Prostate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries

Chen, Sung Lang; Wang, Shao Chuan; Ho, Cheng-Ju; Kao, Yu Lin; Hsieh, Tzuo Yi; Chen, Wen Jung; Chen, Chih‐Jung; Wu, Pei; Ko, Jiunn‐Liang; Lee, Huei; Sung, Wen‐Wei

doi:10.1038/srep40003

Cited by 75 publications

(95 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It, together with breast cancer, the most common cancer and the leading cause of cancer death for women worldwide (10), was the two most studied cancer types. That the incidence rate of prostate cancer was greater in countries with higher GDPPC or more developed areas had been pointed out by many researchers (10)(11)(12)(13). The mortality rate was comparatively low in these countries, yet still higher than less developed regions (10,12,13).…”

Section: Introductionmentioning

confidence: 92%

“…That the incidence rate of prostate cancer was greater in countries with higher GDPPC or more developed areas had been pointed out by many researchers (10)(11)(12)(13). The mortality rate was comparatively low in these countries, yet still higher than less developed regions (10,12,13). As for breast cancer, wealthier countries tended to have higher incidence rate (14,15), with the ASIR in more developed countries two times as high as in less developed countries (10).…”

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

Yang

Zheng

Zhang

et al. 2017

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Objective: In this research, the patterns of cancer incidence and mortality in areas with different gross domestic product per capita (GDPPC) levels in China were explored, using data from population-based cancer registries in 2013, collected by the National Central Cancer Registry (NCCR).Methods: Data from 255 cancer registries were qualified and included in this analysis. Based on the GDPPC data of 2014, cities/counties were divided into 3 levels: high-, middle-and low-GDPPC areas, with 40,000 and 80,000 RMB per year as cut points. We calculated cancer incidences and mortalities in these three levels, stratified by gender and age group. The national population of the Fifth Census in 2000 and Segi's population were applied for age-standardized rates. Results:The crude incidence and mortality rates as well as age-standardized incidence rate (ASIR) showed positive associations with GDPPC level. The age-standardized mortality rate (ASMR) nevertheless showed a negative association with GDPPC level. The ASMR in high-, middle-and low-GDPPC areas was 103.12/100,000, 112.49/100,000 and 117.43/100,000, respectively. Lung cancer was by far the most common cancer in all three GDPPC levels. It was also the leading cause of cancer death, regardless of gender and GDPPC level. Negative associations with GDPPC level were found for the ASIRs of lung, stomach, esophageal and liver cancer, whereas colorectal and breast cancer showed positive associations. Except for breast cancer, the ASMRs of the other five cancers were always higher in middle-and low-GDPPC areas than in high-GDPPC areas. Conclusions:The economic development is one of the main factors of the heavy cancer burden on Chinese population. It would be reasonable to implement cancer control strategies referring to the local GDPPC level.

show abstract

Section: Introductionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 93%

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

Yang

Zheng

Zhang

et al. 2017

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…Similarly, the study in Ghana indicates a better survival in patients with early stages of the diseases at diagnosis (stage I & II) than advanced stages (III & IV) [13]. However, the overall survival rate in this study is lower compared to the studies done in high-income countries [14,15]. The observed discrepancies in survival between countries seem to be largely a result of differences in the availability and accessibility of early diagnosis and treatment.…”

Section: Discussionmentioning

confidence: 49%

Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A retrospective cohort study

et al. 2020

View full text Add to dashboard Cite

Background Globally, the incidence of prostate cancer is increasing, particularly in low-and middleincome countries. It is the most common cancer among men worldwide, with higher mortality in low and middle-income countries. In Ethiopia, it is the second most common cause of cancer morbidity and mortality among men. Despite a few studies done regarding the disease burden, the evidence is scarce about the survival and prognostic determinants of prostate cancer patients in Ethiopia. Thus, this study assessed the survival and prognostic determinants of patients with prostate cancer. Methods We retrospectively followed patients who were newly diagnosed from 2012 to 2016 at the Oncology Department of Tikur Anbessa Specialized Hospital. We extracted the data from patient charts that were available in the cancer registry using a checklist with the help of oncology nurses. Kaplan-Meier survival analyses with the log-rank test were used to estimate and compare the probability of survival among covariate categories. After checking for assumptions, a multivariable Cox regression analysis was performed to identify prognostic determinants of survival. Results The median survival time was 28 months with an overall 2-, 3-and 5-year survival of 57%, 38.9% and 22%, respectively. The overall survival differs according to the clinical stage (P-value<0.01), presence or absence of distant metastasis (P<0.01) and androgen deprivation therapy (ADT) (P<0.05). Cancer stage at diagnosis (adjusted hazard ratio (AHR) = 0.309,

show abstract

“…The increasing trend in PCa incidence reported over the last two decades, as well as differences in the geographic distribution of this value among different countries show a good parallelism with differences in the use of the Prostate Specific Antigen (PSA) assay for PCa diagnosis. The highest number of screenings occurs in Western countries, where the highest incidence is found [3]. In contrast, the incidence of PCa is much lower in Asia and Africa where the PSA screening has not been widely adopted until now.…”

Section: Introductionmentioning

confidence: 99%

Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges

Naponelli¹,

Ramazzina²,

Lenzi³

et al. 2017

Preprint

View full text Add to dashboard Cite

Green Tea Catechins (GTCs) are a family of chemically related compounds usually classified as antioxidant molecules. Epidemiological evidences, supported by interventional studies, highlighted a more than promising role for GTCs in human Prostate Cancer (PCa) chemoprevention.In the last decades many efforts have been made to gain new insights into the mechanism of action of GTCs. Now it is clear that GTCs anticancer action can no longer be simplistically limited to their direct antioxidant/pro-oxidant properties. Recent contributions to the advancement of knowledge in this field have shown that GTCs specifically interact with cellular targets including, cell surface receptors, lipid rafts and endoplasmic reticulum, modulate gene expression through direct effect on transcription factors or indirect epigenetic mechanisms, interfere with intracellular proteostasis at various levels. Many of the effects observed in vitro are dose and cell context dependent and take place at concentration that cannot be achieved in vivo.Poor intestinal absorption together with an extensive systemic and enteric metabolism influence GTCs bioavailability through still poor understood mechanisms. Recent efforts to develop delivery systems that increase GTCs overall bioavailability, by mean of biopolymeric nanoparticles, represent the main way to translate preclinical results in a real clinical scenario for PCa chemoprevention.

show abstract

Prostate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries

Cited by 75 publications

References 18 publications

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A retrospective cohort study

Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges

Contact Info

Product

Resources

About